Research in GE Junction Gastric Cancer – pro
C-MET as target for GE Junction cancer
Since GE Junctions cacners that express HER respond well to Herceptin, there is great interest in targeting molecules, such as the epidermal growth factor receptor, vascular endothelial growth factor receptor, and P13k/Akt/mTor pathway, as well as the insulin-like growth factor receptor, c-Met pathways, fibroblast growth factor receptor, and other pathways. Much remians to be done before clinical therapies based on this concept become available and proven. One study looking at a C-MET inhibitor is: MET111643 ,A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer.
Jochen K. Lennerz, Eunice L. Kwak, Allison Ackerman, Michael Michael, Stephen B. Fox, Kristin Bergethon, Gregory Y. Lauwers, James G. Christensen, Keith D. Wilner, Daniel MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib, JCO VOLUME 29 NUMBER 36 DECEMBER 20 2011
Ajani JA: Gastroesophageal cancers: Progress and problems. J Natl Compr Canc Netw 6:813-814, 2008
nccn.org, Gastric cancer 2012
Read the Layperson version here.